News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Amir Fathi, MD, Massachusetts General Hospital

Articles by Amir Fathi, MD, Massachusetts General Hospital

Optimizing Treatment Selection for Patients with FLT3-ITD AML

ByNaval G. Daver, MD,Amir Fathi, MD, Massachusetts General Hospital,Margaret T. Kasner, MD,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center

July 24th 2023

Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.

Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML

ByNaval G. Daver, MD,Amir Fathi, MD, Massachusetts General Hospital,Margaret T. Kasner, MD,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center

July 17th 2023

Recommendations for community oncologists concerning the treatment of fit patients diagnosed with AML.

Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia

ByNaval G. Daver, MD,Amir Fathi, MD, Massachusetts General Hospital,Margaret T. Kasner, MD,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center

July 17th 2023

Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.

Expert on AML

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

ByAmir Fathi, MD, Massachusetts General Hospital

July 12th 2023

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

An Introduction to Biomarker Testing in Acute Myeloid Leukemia

ByNaval G. Daver, MD,Amir Fathi, MD, Massachusetts General Hospital,Margaret T. Kasner, MD,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center

June 26th 2023

Experienced clinicians highlight the role of biomarker testing in AML for optimal patient care and treatment selection.

An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia

ByNaval G. Daver, MD,Amir Fathi, MD, Massachusetts General Hospital,Margaret T. Kasner, MD,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center

June 26th 2023

Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.

Progress in the Treatment of AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Implications for Treating AML With CC-486

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

CC-486 Maintenance Therapy in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Gemtuzumab for AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

CPX-351 in Newly Diagnosed Secondary AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Differentiation Syndrome and IDH Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

IDH Inhibitors and MDS

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

IDH1/2 Inhibitors for AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

IDH Mutations in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3 Triplet Regimens for AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Monitoring Response to Venetoclax Regimens in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Venetoclax in AML: Safety Profile

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Optimal Use of Venetoclax in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

VIALE Studies in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Utilization of Second-Generation FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Second-Generation FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3-Mutated AML: Midostaurin and Chemotherapy

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3 Genetic Alterations in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Latest Updated Articles

Optimizing Treatment Selection for Patients with FLT3-ITD AML
Published: July 24th 2023 | Updated:
Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML
Published: July 17th 2023 | Updated:
An Introduction to Biomarker Testing in Acute Myeloid Leukemia
Published: June 26th 2023 | Updated:
Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia
Published: July 17th 2023 | Updated:
An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia
Published: June 26th 2023 | Updated:
Implications for Treating AML With CC-486
Published: July 20th 2020 | Updated:

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis